Ligand Pharmaceuticals competitors

Ligand Pharmaceuticals's competitors include MyoKardia, Athersys, Reata Pharmaceuticals and Ironwood Pharmaceuticals
Add company...
Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Founding Date
Founding Date
1987
Founding Date
2012
Founding Date
1995
Founding Date
2002
Founding Date
N/A
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
San Diego, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Locations
Irving, US HQ
Locations
Cambridge, US HQ
Employees
Employees
22
Employees
1024% increase
Employees
60
Employees
75
Employees
674
Valuation ($)
Valuation ($)
5.4 b
Valuation ($)
2.6 b
Valuation ($)
257.8 m
Valuation ($)
N/A
Valuation ($)
2.6 b
Facebook likes
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
475
Facebook likes
184
Facebook likes
18
Twitter followers
Twitter followers
387
Twitter followers
387
Twitter followers
953
Twitter followers
418
Twitter followers
3.1 k

Financial

Revenue (est.)
Revenue (est.)
$141.1m (FY, 2017)
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$274m (FY, 2016)
Net income
Net income
$12.6m (FY, 2017)
Net income
($46m) (FY, 2017)
Net income
N/A
Net income
($47.7m) (FY, 2017)
Net income
($81.7m) (FY, 2016)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents (US)
N/A
Patents (US)
N/A
Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Patents Issued
240 (FY, 2016)
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2017)
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A

Funding

Total funding raised
Total funding raised
$ 225m
Total funding raised
$ 98m
Total funding raised
$ 9m
Total funding raised
$ 300m
Total funding raised
$ 284m
For sources of this data, please see the company profileDownload Excel

View company profiles

MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
60

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Reata Pharmaceuticals
HQ
Irving, US
Employees
75

Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.

View company
Ironwood Pharmaceuticals
HQ
Cambridge, US
Employees
674

Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.

View company